Home » Stocks » IMUX

Immunic, Inc. (IMUX)

Stock Price: $16.39 USD -0.19 (-1.15%)
Updated Feb 24, 2021 3:59 PM EST - Market closed
After-hours: $16.38 -0.01 (-0.06%) Feb 24, 7:29 PM
Market Cap 343.51M
Revenue (ttm) n/a
Net Income (ttm) -40.55M
Shares Out 18.41M
EPS (ttm) -3.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 24
Last Price $16.39
Previous Close $16.58
Change ($) -0.19
Change (%) -1.15%
Day's Open 16.76
Day's Range 16.16 - 16.98
Day's Volume 198,691
52-Week Range 4.19 - 28.21

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 6 days ago

Immunic Inc (NASDAQ: IMUX) has announced top-line data from an investigator-sponsored Phase 2 proof-of-concept trial evaluating IMU-838 in primary sclerosing cholangitis (PSC), a rare liver di...

PRNewsWire - 6 days ago

NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating ...

Benzinga - 1 week ago

Immunic Inc (NASDAQ: IMUX) completes the main analysis of Phase 1 CALVID-1 trial evaluating its lead asset, IMU-838. It is a selective oral DHODH inhibitor used in hospitalized patients with m...

PRNewsWire - 1 week ago

NEW YORK, Feb. 17, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating ...

PRNewsWire - 1 week ago

NEW YORK, Feb. 11, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating ...

PRNewsWire - 1 month ago

NEW YORK, Jan. 5, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating c...

PRNewsWire - 2 months ago

NEW YORK, Dec. 14, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating ...

PRNewsWire - 3 months ago

NEW YORK, Nov. 24, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating ...

PRNewsWire - 3 months ago

NEW YORK, Nov. 17, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating ...

PRNewsWire - 3 months ago

NEW YORK, Nov. 10, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating ...

PRNewsWire - 3 months ago

NEW YORK, Nov. 2, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating c...

PRNewsWire - 4 months ago

LUXEMBOURG and GRÄFELFING, Germany and NEW YORK, Oct. 20, 2020 /PRNewswire/ -- The European Investment Bank (EIB) and Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company d...

PRNewsWire - 4 months ago

NEW YORK, Sept. 29, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating...

PRNewsWire - 4 months ago

NEW YORK, Sept. 28, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating...

PRNewsWire - 5 months ago

NEW YORK, Sept. 11, 2020 /PRNewswire/ -- Immunic, Inc.

PRNewsWire - 5 months ago

NEW YORK, Sept. 8, 2020 /PRNewswire/ -- Immunic, Inc.

The Motley Fool - 5 months ago

An analyst says buy.

PRNewsWire - 6 months ago

NEW YORK, Aug. 20, 2020 /PRNewswire/ -- Immunic, Inc.

PRNewsWire - 6 months ago

NEW YORK, Aug. 10, 2020 /PRNewswire/ -- Immunic, Inc.

PRNewsWire - 6 months ago

NEW YORK, Aug. 4, 2020 /PRNewswire/ -- Immunic, Inc.

PRNewsWire - 6 months ago

NEW YORK, Aug. 3, 2020 /PRNewswire/ -- Immunic, Inc.

Seeking Alpha - 6 months ago

Immunic, Inc. (IMUX) CEO Daniel Vitt on Q2 2020 Results - Earnings Call Transcript

Benzinga - 6 months ago

Immunic Inc (NASDAQ: IMUX) shares are surging following a positive clinical readout.

PRNewsWire - 6 months ago

NEW YORK, July 30, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chroni...

PRNewsWire - 6 months ago

NEW YORK, July 29, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chroni...

PRNewsWire - 6 months ago

NEW YORK, July 27, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chroni...

Seeking Alpha - 7 months ago

A cocktail of antiviral agents is more likely than a vaccine (or vaccines) to be effective in treating SARS-CoV-2 infections and preventing COVID-19.

Other stocks mentioned: BCRX, BNTX, BSGM, CYDY, EIGR, GILD, PFE, REGN
PRNewsWire - 8 months ago

NEW YORK, June 22, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chroni...

PRNewsWire - 8 months ago

NEW YORK, June 15, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chroni...

Zacks Investment Research - 8 months ago

Immunic (IMUX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 8 months ago

Immunic (IMUX) gets a FDA allowance to begin a phase II study on its DHODH inhibitor IMU-838 for addressing COVID-19 in the United States. Top-line results on the same are awaited later this y...

PRNewsWire - 8 months ago

NEW YORK, June 10, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chroni...

PRNewsWire - 8 months ago

NEW YORK, June 9, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic...

PRNewsWire - 8 months ago

NEW YORK, June 9, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic...

PRNewsWire - 8 months ago

NEW YORK, May 29, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic...

PRNewsWire - 9 months ago

NEW YORK, May 19, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic...

About IMUX

Immunic, a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase, which is in Phase 2 clinical development for treatment of ulcerative colitis ... [Read more...]

Industry
Biotechnology
CEO
Daniel Vitt
Employees
26
Stock Exchange
NASDAQ
Ticker Symbol
IMUX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for Immunic stock is "Buy." The 12-month stock price forecast is 60.83, which is an increase of 271.14% from the latest price.

Price Target
$60.83
(271.14% upside)
Analyst Consensus: Buy